Daklinza troubled with the September launch of Sovaldi
It seems that a domestic approval of the hepatitis type C treatment, ‘Sovaldi(generic name: sofosbuvir),’ will be made between September and October. As the approval of Sovaldi has come closer, BMS Korea has also been impatient.
A person in Gilead Sciences has recently unveiled that the Ministry...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
